Literature DB >> 17606963

When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection?

Bulent Degertekin, Anna S F Lok.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17606963     DOI： 10.7326/0003-4819-147-1-200707030-00011

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  4 in total

1.  A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.

Authors:  D Eldon Spackman; David L Veenstra
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 2.  Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.

Authors:  Jean-Michel Pawlotsky; Geoffrey Dusheiko; Angelos Hatzakis; Daryl Lau; George Lau; T Jake Liang; Stephen Locarnini; Paul Martin; Douglas D Richman; Fabien Zoulim
Journal:  Gastroenterology       Date:  2007-11-28       Impact factor: 22.682

3.  Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers.

Authors:  Nimer Assy; Zaza Beniashvili; Agness Djibre; Gattas Nasser; Maria Grosovski; William Nseir
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

4.  Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriers.

Authors:  Bushra Ijaz; Waqar Ahmad; Fouzia T Javed; Sana Gull; Sajida Hassan
Journal:  Virol J       Date:  2011-02-27       Impact factor: 4.099
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.